دورية أكاديمية
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.
| العنوان: | Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol. |
|---|---|
| المؤلفون: | Spiekman IAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands., Geurts BS; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Zeverijn LJ; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Wit GF; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands., de Leng WWJ; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, The Netherlands., Jansen AML; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, The Netherlands., Kusters B; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Beerepoot LV; Department of Internal Medicine, ETZ Hospital (Elisabeth-TweeSteden Ziekenhuis), Tilburg, The Netherlands., de Vos FYFL; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., de Groot DA; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands., de Groot JWB; Isala Oncology Center, Isala, Zwolle, The Netherlands., Hoeben A; Division of Medical Oncology, Department of Internal Medicine, GROW School of Oncology and Development Biology, Maastricht University Center+, Maastricht, The Netherlands., Buter J; Department of Medical Oncology, Amsterdam University Medical Center, Location VuMC, Amsterdam, The Netherlands., Gelderblom HAJ; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Voest EE; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam,The Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands. |
| المصدر: | The oncologist [Oncologist] 2024 May 03; Vol. 29 (5), pp. 431-440. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2022- : Oxford : Oxford University Press Original Publication: Dayton, Ohio : AlphaMed Press, c1996- |
| مواضيع طبية MeSH: | Panitumumab*/therapeutic use , Panitumumab*/adverse effects , Panitumumab*/pharmacology , Glioblastoma*/drug therapy , Glioblastoma*/genetics , Glioblastoma*/pathology , Glioblastoma*/mortality, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Brain Neoplasms/drug therapy ; Brain Neoplasms/genetics ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/adverse effects ; ras Proteins/genetics ; raf Kinases/genetics ; raf Kinases/antagonists & inhibitors |
| مستخلص: | Background: The prognosis of malignant primary high-grade brain tumors, predominantly glioblastomas, is poor despite intensive multimodality treatment options. In more than 50% of patients with glioblastomas, potentially targetable mutations are present, including rearrangements, altered splicing, and/or focal amplifications of epidermal growth factor receptor (EGFR) by signaling through the RAF/RAS pathway. We studied whether treatment with the clinically available anti-EGFR monoclonal antibody panitumumab provides clinical benefit for patients with RAF/RAS-wild-type (wt) glioblastomas in the Drug Rediscovery Protocol (DRUP). Methods: Patients with progression of treatment refractory RAF/RASwt glioblastoma were included for treatment with panitumumab in DRUP when measurable according to RANO criteria. The primary endpoints of this study are clinical benefit (CB: defined as confirmed objective response [OR] or stable disease [SD] ≥ 16 weeks) and safety. Patients were enrolled using a Simon-like 2-stage model, with 8 patients in stage 1 and up to 24 patients in stage 2 if at least 1 in 8 patients had CB in stage 1. Results: Between 03-2018 and 02-2022, 24 evaluable patients were treated. CB was observed in 5 patients (21%), including 2 patients with partial response (8.3%) and 3 patients with SD ≥ 16 weeks (12.5%). After median follow-up of 15 months, median progression-free survival and overall survival were 1.7 months (95% CI 1.6-2.1 months) and 4.5 months (95% CI 2.9-8.6 months), respectively. No unexpected toxicities were observed. Conclusions: Panitumumab treatment provides limited CB in patients with recurrent RAF/RASwt glioblastoma precluding further development of this therapeutic strategy. (© The Author(s) 2023. Published by Oxford University Press.) |
| References: | Crit Rev Oncol Hematol. 2016 Mar;99:389-408. (PMID: 26830009) Neurooncol Adv. 2021 Aug 03;3(1):vdab102. (PMID: 34549181) Cancer Cell. 2015 Sep 14;28(3):318-28. (PMID: 26373279) J Clin Oncol. 2009 Feb 10;27(5):740-5. (PMID: 19114704) Eur J Cancer. 2015 Mar;51(4):522-532. (PMID: 25616647) Cancer Discov. 2013 May;3(5):534-47. (PMID: 23533263) Neuro Oncol. 2013 Nov;15 Suppl 2:ii1-56. (PMID: 24137015) J Neurooncol. 2017 Oct;135(1):183-192. (PMID: 28730289) J Clin Neurosci. 2009 Jun;16(6):748-54. (PMID: 19324552) J Clin Oncol. 2009 Oct 1;27(28):4733-40. (PMID: 19720927) Neuro Oncol. 2020 May 15;22(5):684-693. (PMID: 31747009) J Nucl Med. 2019 May;60(5):617-622. (PMID: 30315146) Science. 2007 Oct 12;318(5848):287-90. (PMID: 17872411) Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5705-9. (PMID: 8202551) J Clin Oncol. 2017 Jul 20;35(21):2439-2449. (PMID: 28640707) J Clin Oncol. 2001 Sep 15;19(18 Suppl):32S-40S. (PMID: 11560969) Nat Genet. 2016 Jul;48(7):768-76. (PMID: 27270107) Nature. 2012 Jun 28;486(7404):537-40. (PMID: 22722843) Stat Med. 2004 Feb 28;23(4):561-9. (PMID: 14755389) Medicine (Baltimore). 2021 Mar 12;100(10):e25046. (PMID: 33725888) J Clin Oncol. 2004 Jan 1;22(1):133-42. (PMID: 14638850) Pharmacol Res. 2021 Sep;171:105780. (PMID: 34302977) J Clin Oncol. 2020 Jan 1;38(1):81-99. (PMID: 31743054) Ann Oncol. 2009 Sep;20(9):1596-1603. (PMID: 19491283) Cell. 2013 Oct 10;155(2):462-77. (PMID: 24120142) JAMA. 2023 Feb 21;329(7):574-587. (PMID: 36809318) N Engl J Med. 2017 Nov 16;377(20):1954-1963. (PMID: 29141164) Nat Rev Cancer. 2013 Sep;13(9):663-73. (PMID: 23949426) Neuro Oncol. 2021 Aug 2;23(8):1231-1251. (PMID: 34185076) Nature. 2008 Oct 23;455(7216):1061-8. (PMID: 18772890) Neuro Oncol. 2010 May;12(5):508-16. (PMID: 20406901) J Clin Oncol. 2016 Jan 10;34(2):179-85. (PMID: 26438111) Science. 2007 May 18;316(5827):1039-43. (PMID: 17463250) J Clin Oncol. 2009 Mar 10;27(8):1268-74. (PMID: 19204207) Oncogene. 2018 Mar;37(12):1561-1575. (PMID: 29321659) J Clin Oncol. 2005 Mar 20;23(9):1803-10. (PMID: 15677699) N Engl J Med. 2005 Nov 10;353(19):2012-24. (PMID: 16282176) Acta Neuropathol. 2016 Jun;131(6):803-20. (PMID: 27157931) N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009) Nature. 2019 Oct;574(7776):127-131. (PMID: 31570881) Clin Cancer Res. 2022 Apr 14;28(8):1595-1602. (PMID: 35165100) |
| معلومات مُعتمدة: | 10014 Dutch Cancer Society |
| فهرسة مساهمة: | Keywords: RAF/RAS-wildtype; DRUP trial; glioblastoma; panitumumab; precision medicine |
| المشرفين على المادة: | 6A901E312A (Panitumumab) 0 (Antineoplastic Agents, Immunological) EC 3.6.5.2 (ras Proteins) EC 2.7.11.1 (raf Kinases) |
| تواريخ الأحداث: | Date Created: 20231218 Date Completed: 20240503 Latest Revision: 20240523 |
| رمز التحديث: | 20240523 |
| مُعرف محوري في PubMed: | PMC11067815 |
| DOI: | 10.1093/oncolo/oyad320 |
| PMID: | 38109296 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyad320 |